跳至主要内容
临床试验/NCT05933161
NCT05933161招募中不适用

GLYcemic Control Evaluation by Continuous Glucose Monitor Compared With a1C in Left Ventricular Assist Device-supported Patients (GLYCEM1C-LVAD)

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年11月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
Mayo Clinic
入组人数
20
试验地点
2
主要终点
Average glucose values based on continuous glucose monitoring

研究概览

简要总结

The study is being conducted to understand if the hemoglobin A1c, a measurement of control of blood sugars over a 3-month time, is valid in patients with Left Ventricular Assist Devices (LVADs) in place. To understand whether it is an adequate measurement, the investigators will compare the A1c to results from a continuous glucose monitor (CGM) measurement of blood sugars. By monitoring blood sugars continuously, the investigators will also assess whether they can get better control of blood sugars with a CGM, including avoiding low blood sugars.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Prior implantation of contemporary, centrifugal flow LVAD (HeartWare or HeartMate 3) at any time after 2010
  • Diagnosis of type II diabetes mellitus
  • Any antihyperglycemic regimen
  • Greater than 3 months out from LVAD implantation
  • Capable of utilizing smartphone device for LibreLink app for uploading glycemic data
  • Patients may be enrolled who have preexisting CGM in place.

排除标准

  • Type I diabetics
  • Unable to return at 3 month evaluation
  • Unwillingness to participate

研究组 & 干预措施

Left Ventricular Assist Device (LVAD) supported Type 2 Diabetes Mellitus (T2DM) Subjects

Subjects diagnosed with T2DM who have a LVAD will be provided a Freestyle Libre 3 CGM.

干预措施: Freestyle Libre 3 Continuous Glucose Monitor (CGM) (Device)

结局指标

主要结局

Average glucose values based on continuous glucose monitoring

时间窗: 3 months

Average level of blood sugar reported in mg/dL obtained via the Freestyle Libre 3 CGM over a 3 month period.

Estimated average glucose (eAG) values based on fructosamine lab values

时间窗: 3 months

Estimated average level of blood sugar reported in mg/dL based on conversion of fructosamine lab values (eAG= 28.7\*(0.017 x fructosamine + 1.61) - 46.7) collected at the 3-month visit.

Estimated average glucose (eAG) values based on hemoglobin-A1c lab values

时间窗: 3 months

Estimated average level of blood sugar reported in mg/dL based on conversion of hemoglobin-A1c lab values (eAG=28.7\*A1C - 46.7) collected at the 3-month visit.

次要结局

  • Number of hypoglycemic unawareness episodes(3 months)
  • Number of adjustments of antihyperglycemic agents(3 months)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew N Rosenbaum

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验